Cholinesterase inhibitors for Parkinson's disease: A systematic review and meta-analysis

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 7, 2015, Pages 767-773

  Pagano, Gennaro ^a,b   Rengo, Giuseppe ^c   Pasqualetti, Giuseppe ^d   Femminella, Grazia Daniela ^b   Monzani, Fabio ^d   Ferrara, Nicola ^b,c   Tagliati, Michele ^e  

^a UNIVERSITY OF MOLISE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c IRCCS   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; BEHAVIOR DISORDER; BIBLIOGRAPHIC DATABASE; COGNITIVE DEFECT; COHORT ANALYSIS; DISABILITY; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; FALL RISK ASSESSMENT; HIGH RISK POPULATION; HUMAN; META ANALYSIS; MINI MENTAL STATE EXAMINATION; MORTALITY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; TREATMENT OUTCOME;

CHOLINESTERASE INHIBITORS; HUMANS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 84939232339     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-308764     Document Type: Article

References (42)

1. Hindle JV Ageing, neurodegeneration and Parkinson's disease. Age Ageing 2010; 39: 156-61.
2. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4.
3. Chaudhuri KR, Healy DG, Schapira AH, et al. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5: 235-45.
4. Aarsland D, Ballard C, Rongve A, et al. Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia. Curr Neurol Neurosci Rep 2012; 12: 492-501.
5. Winter Y, von Campenhausen S, Arend M, et al. Health-related quality of life and its determinants in Parkinson's disease: results of an Italian cohort study. Parkinsonism Relat Disord 2011; 17: 265-69.
6. Ohara K, Kondo N. Changes of monoamines in post-mortem brains from patients with diffuse Lewy body disease. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 311-17.
7. Calabresi P, Picconi B, Parnetti L, et al. A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. Lancet Neurol 2006; 5: 974-83.
8. Tagliavini F, Pilleri G, Bouras C, et al. The basal nucleus of Meynert in idiopathic Parkinson's disease. Acta Neurol Scand 1984; 70: 20-8.
9. Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985; 48: 413-21.
10. Stolze H, Klebe S, Baecker C, et al. Prevalence of gait disorders in hospitalized neurological patients. Mov Disord 2005; 20: 89-94.
11. Welmerink DB, Longstreth WT Jr, Lyles MF, et al. Cognition and the risk of hospitalization for serious falls in the elderly: results from the Cardiovascular Health Study. J Gerontol A Biol Sci Med Sci 2010; 65: 1242-9.
12. Rudzińska M, Bukowczan S, Stozek J, et al. The incidence and risk factors of falls in Parkinson disease: prospective study. Neurol Neurochir Pol 2013; 47: 431-7.
13. Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837-44.
14. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011; 26(Suppl 3): S42-80.
15. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA 2014; 311: 1670-83.
16. Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev 2012; 3: CD006504.
17. Chung KA, Lobb BM, Nutt JG, et al. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 2010; 75: 1263-9.
18. Wang HF, Yu JT, Tang SW, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 2015; 86: 135-43.
19. Burn DJ, Rowan EN, Minett T, et al. Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: a cross-sectional comparative study. Mov Disord 2003; 18: 884-9.
20. Ballard C, Ziabreva I, Perry R, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006; 67: 1931-4.
21. Edison P, Ahmed I, Fan Z, et al. Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. Neuropsychopharmacology 2013; 38: 938-49.
22. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Ann Intern Med 2009; 151: 264-9.
23. Rengo G, Pagano G, Squizzato A, et al. Oral anticoagulation therapy in heart failure patients in sinus rhythm: a systematic review and meta-analysis. PLoS ONE 2013; 8: e52952.
24. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. version 5.1.0 (updated March 2011). http://www.cochrane-handbook.org The Cochrane Collaboration
25. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 2001; 323: 101-5.
26. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ 1997; 315: 1533-7.
27. Whitehead A. Meta-analysis of controlled clinical trials. John Wiley & Sons, 2002. doi: 10.1002/0470854200
28. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
29. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
30. Tobias A. Assessing the influence of a single study in meta-analysis. Stata Tech Bull 1999; 47: 15-17.
31. Sharp SJ Meta-analysis regression. Stata Tech Bull 1998; 42: 16-22.
32. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999; 18: 2693-708.
33. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-18.
34. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76: 934-9.
35. Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord 2012; 27: 1230-8.
36. Ruberg M, Rieger F, Villageois A, et al. Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson's disease. Brain Res 1986; 362: 83-91.
37. Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson's disease. Functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 65: 1716-22.
38. Di Santo SG, Prinelli F, Adorni F, et al. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease. J Alzheimers Dis 2013; 35: 349-61.
39. Oregon Health and Science University. A randomized, doubleblind, placebo controlled, crossover study to evaluate the effect of donepezil on gait and balance in Parkinson's disease. Fox Trial Finder [internet]. New York, NY: The Michael J. Fox Foundation for Parkinson's Research, 2011. [cited 2012 Jul 16]. Available at: http://foxtrialfinder.michaeljfox.org/trial/2684
40. Whone A. Phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen. Fox Trial Finder [internet]. New York, NY: The Michael J. Fox Foundation for Parkinson's Research, 2011. [cited 2012 Jul 16]. http://foxtrialfinder.michaeljfox.org/trial/2641
41. Jones RW A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Int J Geriatr Psychiatry 2010; 25: 547-53.
42. Oertel W, Poewe W, Wolters E, et al. Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension. Drug Saf 2008; 31: 79-94.